Top

International Journal of Emergency Medicine

Published in:

01-12-2021 | Intoxication | Review

The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review

Authors: Kevin M. Takakuwa, Raquel M. Schears

Published in: International Journal of Emergency Medicine | Issue 1/2021

Abstract

Background

Cannabis is the most prevalent illegal drug used and the second most common cause of ED drug-related complaints in the USA. Recently, newer more potent strains, concentrated THC products, and consumption methods have become available.

Objective

Our first objective was to define cannabis use in the USA and provide a summary background on its current preparations, pharmacokinetics, vital sign and physical exam findings, adverse effects, and laboratory testing. Our second objective, using the aforementioned summary as relevant background information, was to present and summarize the care and treatment of the most commonly reported cannabis-related topics relevant to ED physicians.

Methods

We first performed an extensive literature search of peer-reviewed publications using New PubMed and Cochrane Central Register of Controlled Trials to identify the most commonly reported cannabis-related topics in emergency care. Once the six topic areas were identified, we undertook an extensive narrative literature review for each section of this paper using New PubMed and Cochrane Central Register of Controlled Trials from the inception of the databases to September 30, 2020.

Results

The six subject areas that were most frequently reported in the medical literature relevant to cannabis-related ED care were acute intoxication/overdose, pediatric exposure, cannabinoid hyperemesis syndrome, cannabis withdrawal, e-cigarette or vaping product use-associated lung injury (EVALI), and synthetic cannabinoids.

Conclusion

As cannabis becomes more widely available with the adoption of state medical cannabis laws, ED-related cannabis visits will likely rise. While cannabis has historically been considered a relatively safe drug, increased legal and illegal access to newer formulations of higher potency products and consumption methods have altered the management and approach to ED patient care and forced physicians to become more vigilant about recognizing and treating some new cannabis-related life-threatening conditions.

Substance Abuse and Mental Health Services Administration. September 7, 2018. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHDetailedTabs2017/NSDUHDetailedTabs2017.pdf. Tables 1.1A and 1.1B. Accessed 4 Feb 2019.

United Nations Office on Drugs and Crime. https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_1_EXSUM.pdf. Page 11. Accessed 10 Feb 2019.

Substance Abuse and Mental Health Service Administration. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug- related emergency department visits. https://www.samhsa.gov/data/sites/default/files/DAWN127/DAWN127/sr127-DAWN-highlights.pdf. Page 3. Accessed 24 Jan 2019.

National Hospital Ambulatory Medical Care Survey 2011 Emergency Department Summary. https://www.cdc.gov/nchs/data/ahcd/nhamcs_emergency/2011_ed_web_tables.pdf. Table 2. Accessed 26 Jan 2019.

NCHS, National Hospital Care Survey, 2013. https://www.cdc.gov/nchs/data/nhsr/nhsr114.pdf. Accessed 26 Jan 2019.

Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila). 2019;57(12):1220–413 PubMed PMID: 31752545.CrossRef

Takakuwa KM. A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement. Int J Drug Policy. 2020;79:102749. https://doi.org/10.1016/j.drugpo.2020.102749.CrossRefPubMed

US Drug Enforcement Agency (DEA). Office of Diversion Control. Controlled Substance Schedules and List of Controlled Substances. https://www.deadiversion.usdoj.gov/schedules/. Accessed 9 May 2019.

State medical marijuana laws. National Conference of State Legislatures Web site. http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Accessed 11 Jan 2021.

10.

Zhu H, Wu L. Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011. J Addict Med. 2016;10(6):429–36. https://doi.org/10.1097/ADM.0000000000000256.CrossRefPubMedPubMedCentral

11.

Kim HS, Hall KE, Genco EK, et al. Marijuana tourism and emergency department visits in Colorado. N Engl J Med. 2016;374(8):797–8. https://doi.org/10.1056/NEJMc1515009.CrossRefPubMedPubMedCentral

12.

Shen JJ, Shan G, Kim PC, et al. Trends and related factors of cannabis-associated emergency department visits in the United States: 2006-2014. J Addict Med. 2019;13(3):193–200. https://doi.org/10.1097/ADM.0000000000000479.CrossRefPubMed

13.

Wong KU, Baum CR. Acute Cannabis Toxicity. Pediatr Emerg Care. 2019;35(11):799–804. https://doi.org/10.1097/PEC.0000000000001970.CrossRefPubMed

14.

Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646–7. https://doi.org/10.1021/ja01062a046.CrossRef

15.

ElSohly MA. Potency Monitoring Program quarterly report no 123 — reporting period: 09/16/2013-12/15/2013. Oxford: University of Mississippi, National Center for Natural Products Research; 2014.

16.

ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613–9. https://doi.org/10.1016/j.biopsych.2016.01.004.CrossRefPubMedPubMedCentral

17.

Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60.CrossRefPubMed

18.

Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med. 1972;287:209–12.CrossRefPubMed

19.

Gash A, Karliner JS, Janowsky D, Lake CR. Effects of smoking marihuana on left ventricular performance and plasma norepinephrine: studies in normal men. Ann Intern Med. 1978;89:448–52.CrossRefPubMed

20.

Jones RT. Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002;42(S1):58S–63S.CrossRefPubMed

21.

Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 2014;136:85–91. https://doi.org/10.1016/j.drugalcdep.2013.12.013.CrossRefPubMedPubMedCentral

22.

Vachon L, FitzGerald MX, Solliday NH, Gould IA, Gaensler EA. Single-dose effects of marihuana smoke. Bronchial dynamics and respiratory-center sensitivity in normal subjects. N Engl J Med. 1973;288(19):985–9.CrossRefPubMed

23.

Franz CA, Frishman WH. Marijuana use and cardiovascular disease. Cardiol Rev. 2016;24:158–62.CrossRefPubMed

24.

Alshaarawy O, Elbaz HA. Cannabis use and blood pressure levels: United States National Health and Nutrition Examination Survey, 2005-2012. J Hypertens. 2016;34(8):1507–12. https://doi.org/10.1097/HJH.0000000000000990.CrossRefPubMedPubMedCentral

25.

Zwillich CW, Doekel R, Hammill S, Weil JV. The effects of smoked marijuana on metabolism and respiratory control. Am Rev Respir Dis. 1978;118(5):885–91.PubMed

26.

Kibby T, Halcomb SE. Toxicology observation: nystagmus after marijuana use. J Forensic Legal Med. 2013;20(4):345–6. https://doi.org/10.1016/j.jflm.2012.07.014.CrossRef

27.

Grotenhermen F. Effects of cannabis and the cannabinoids. In: Grotenhermen F, Russo EB, editors. Cannabis and cannabinoids: Pharmacology, toxicology, and therapeutic potential. Binghamton: The Haworth Press, Inc.; 2002.

28.

Tashkin DP, Shapiro BJ. FrankIM. Acute pulmonary physiologic effects of smoked marijuana and oral Δ9-tetrahydrocannabinol in healthy young men. N Engl J Med. 1973;289(7):336–41. https://doi.org/10.1056/nejm197308162890702.CrossRefPubMed

29.

Wert RC, Raulin ML. The chronic cerebral effects of cannabis use. I. Methodological issues and neurological findings. Int J Addict. 1986;21(6):605–28.CrossRefPubMed

30.

Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56:1059–68. https://doi.org/10.1111/j.1365-2044.2001.02269.x.CrossRefPubMed

31.

Richards JR, Smith NE, Moulin AK. Unintentional cannabis ingestion in children: A systematic review. J Pediatr. 2017;190:142–52. https://doi.org/10.1016/j.jpeds.2017.07.005.CrossRefPubMed

32.

Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(Suppl 1):S163–71.CrossRefPubMedPubMedCentral

33.

Noble MJ, Hedberg K, Hendrickson RG. Acute cannabis toxicity. Clin Toxicol (Phila). 2019;57:735–42.CrossRef

34.

Hendrickson RG, Noble MJ. Cardiovascular effects of inhaled and ingested cannabis products. North American Congress of Clinical Toxicology (NACCT) Abstracts 2019. Clin Toxicol (Phila). 2019;57(10):1009.

35.

Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669–78. https://doi.org/10.1503/cmaj.071178.CrossRefPubMedPubMedCentral

36.

Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep. 2016;18(2):12. https://doi.org/10.1007/s11920-015-0657-y.CrossRefPubMed

37.

Keup W. Psychotic symptoms due to cannabis abuse: A survey of newly admitted mental patients. Dis Nerv Syst. 1970;31(2):119–26.PubMed

38.

Andréasson S, Engström A, Allebeck P, Rydberg U. Cannabis and schizophrenia: A longitudinal study of swedish conscripts. Lancet. 1987;330:1483–6.CrossRef

39.

Johns A. Psychiatric effects of cannabis. BJP. 2001;178:116–22. https://doi.org/10.1192/bjp.178.2.116.CrossRef

40.

Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry. 2004;184:110–7.CrossRefPubMed

41.

Fergusson DM, Poulton R, Smith PF, Boden JM. Cannabis and psychosis. BMJ. 2006;332:172–5.CrossRefPubMedPubMedCentral

42.

Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19:187–94. https://doi.org/10.1177/0269881105049040.CrossRefPubMed

43.

Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–9. https://doi.org/10.1093/schbul/sbw003.CrossRefPubMedPubMedCentral

44.

Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6:427–36.CrossRefPubMedPubMedCentral

45.

Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–76. https://doi.org/10.4065/83.1.66.CrossRefPubMed

46.

Urine testing for detection of marijuana: An advisory. MMWR. 1983;32(36):469–71 https://www.cdc.gov/mmwr/preview/mmwrhtml/00000138.htm. Accessed 28 Apr 2019.

47.

Hawks RL, Chiang CN, editors. Urine testing for drugs of abuse. NIDA Research Monograph. Rockville MD; 1986. p. 73.

48.

Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26:200–5.CrossRefPubMed

49.

Sharma P, Murthy P, Bharath MMS. Chemistry, metabolism, and toxicology of cannabis: Clinical implications. Iran J Psychiatry. 2012;7(4):149–56.PubMedPubMedCentral

50.

McGuigan MA. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LS, Flomenbaum NE, editors. Cannabinoids, in Goldfrank's Toxicologic Emergencies. 9th ed. New York: McGraw Hill; 2011. p. 1181.

51.

Monte AA, Shelton SK, Mills E, et al. Acute illness associated with cannabis use, by route of exposure: An observational study. Ann Intern Med. 2019;170(8):531–7. https://doi.org/10.7326/M18-2809.CrossRefPubMedPubMedCentral

52.

Vo KT, Horng H, Li K, Ho RY, Wu AHB, Lynch KL, Smollin CG. Cannabis intoxication case series: The dangers of edibles containing tetrahydrocannabinol. Ann Emerg Med. 2018;71(3):306–13. https://doi.org/10.1016/j.annemergmed.2017.09.008.CrossRefPubMed

53.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.CrossRef

54.

Dines AM, Wood DM, Galicia M, Yates CM, Heyerdahl F, Hovda KE, Giraudon I, Sedefov R, Euro-DEN Research Group, Dargan PI. Presentations to the Emergency Department Following Cannabis use--a Multi-Centre Case Series from Ten European Countries. J Med Toxicol. 2015;11(4):415–21. https://doi.org/10.1007/s13181-014-0460-x.CrossRefPubMedPubMedCentral

55.

Schmid Y, Scholz I, Mueller L, et al. Emergency department presentations related to acute toxicity following recreational use of cannabis products in Switzerland. Drug Alcohol Depend. 2020;206:107726. https://doi.org/10.1016/j.drugalcdep.2019.107726.CrossRefPubMed

56.

Rao DP, Abramovici H, Crain J, Do MT, McFaull S, Thompson W. The lows of getting high: sentinel surveillance of injuries associated with cannabis and other substance use. Can J Public Health. 2018;109(2):155–63. https://doi.org/10.17269/s41997-018-0027-8.CrossRefPubMedPubMedCentral

57.

Charles R, Holt S, Kirkham N. Myocardial infarction and marijuana. Clin Toxicol. 1979;14(4):433–8. https://doi.org/10.3109/15563657909010604.CrossRefPubMed

58.

Hartung B, Kauferstein S, Ritz-Timme S, Daldrup T. Sudden unexpected death under acute influence of cannabis. Forensic Sci Int. 2014;237:e11–3.CrossRefPubMed

59.

Casier I, Vanduynhoven P, Haine S, Vrints C, Jorens PG. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta Cardiol. 2014;69(2):131–6.CrossRefPubMed

60.

Bachs L, Mørland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int. 2001;124:200–3.CrossRefPubMed

61.

Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review. Curr Atheroscler Rep. 2017;19(6):26. https://doi.org/10.1007/s11883-017-0663-0.CrossRefPubMed

62.

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805–9.CrossRefPubMed

63.

Frost L, Mostofsky E, Rosenbloom JI, Mukamal KJ, Mittleman MA. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am Heart J. 2013;165(2):170–5. https://doi.org/10.1016/j.ahj.2012.11.007.CrossRefPubMed

64.

Richards JR, Bing ML, Moulin AK, Elder JW, Rominski RT, Summers PJ, Laurin EG. Cannabis use and acute coronary syndrome. Clin Toxicol (Phila). 2019:1–11. https://doi.org/10.1080/15563650.2019.1601735.

65.

Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S. Associations between marijuana use and cardiovascular risk factors and outcomes: A systematic review. Ann Intern Med. 2018;168(3):187–94. https://doi.org/10.7326/M17-1548.CrossRefPubMedPubMedCentral

66.

Pradhan RR, Pradhan SR, Mandal S, et al. A systematic review of marijuana use and outcomes in patients with myocardial infarction. Cureus. 2018;10:e3333.PubMedPubMedCentral

67.

Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42(11 Suppl):64S–70S.CrossRefPubMed

68.

Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017;9(7):2079–92. https://doi.org/10.21037/jtd.2017.06.104.CrossRefPubMedPubMedCentral

69.

Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: Speculation or scientific certainty? Int J Cardiol. 2007;118:141–4.CrossRefPubMed

70.

Saunders A, Stevenson RS. Marijuana lollipop-induced myocardial infarction. Can J Cardiol. 2019;35(2):229.e1–3. https://doi.org/10.1016/j.cjca.2018.11.033.CrossRef

71.

California Cannabis Portal. Transition period requirements. https://cannabis.ca.gov/2018/06/06/transition-period-requirements/. Accessed 11 July 2019

72.

Denver Public Health. Facts about marijuana edibles and your health. Accessed 11 July 2019 at http://www.denverpublichealth.org/community-health-promotion/substance-misuse/marijuana-edible-facts

73.

Lindsay AC, Foale RA, Warren O, Henry JA. Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol. 2005;104(2):230–2. https://doi.org/10.1016/j.ijcard.2004.10.038.CrossRefPubMed

74.

Cappelli F, Lazzeri C, Gensini GF, Valente S. Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc Med. 2008;9(7):725–8. https://doi.org/10.2459/JCM.0b013e3282f2cd0d.CrossRef

75.

Richards JR, Blohm E, Toles KA, Jarman AF, Ely DF, Elder JW. The association of cannabis use and cardiac dysrhythmias: a systematic review. Clin Toxicol (Phila). 2020;58(9):861–9. https://doi.org/10.1080/15563650.2020.1743847.CrossRef

76.

Claudet I, Mouvier S, Labadie M, et al. Unintentional cannabis intoxication in toddlers. Pediatrics. 2017;140(3). https://doi.org/10.1542/peds.2017-0017.

77.

Takakuwa KM, Schears RM. A history of the US medical cannabis movement and its importance to pediatricians: science versus politics in medicine’s greatest catch-22. Clin Pediatr (Phila). 2019;58(14):1473–7. https://doi.org/10.1177/0009922819875550.CrossRef

78.

Meier MH, Docherty M, Leischow SJ, Grimm KJ, Pardini D. Cannabis concentrate use in adolescents. Pediatrics. 2019;144(3):e20190338. https://doi.org/10.1542/peds.2019-0338.CrossRefPubMed

79.

Wang GS, Roosevelt G, Heard H. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr. 2013;167:630–3.CrossRefPubMed

80.

Thomas AA, Von Derau K, Bradford MC, Moser E, Garrard A, Mazor S. Unintentional pediatric marijuana exposures prior to and after legalization and commercial availability of recreational marijuana in Washington state. J Emerg Med. 2019;56(4):398–404. https://doi.org/10.1016/j.jemermed.2019.01.004.CrossRefPubMed

81.

Blohm E, Sell P, Neavyn M. Cannabinoid toxicity in pediatrics. Curr Opin Pediatr. 2019;31(2):256–61. https://doi.org/10.1097/mop.0000000000000739.CrossRefPubMed

82.

Whitehill JM, Harrington C, Lang CJ, Chary M, Bhutta WA, Burns MM. Incidence of pediatric cannabis exposure among children and teenagers aged 0 to 19 years before and after medical marijuana legalization in Massachusetts. JAMA Netw Open. 2019;2(8):e199456. https://doi.org/10.1001/jamanetworkopen.2019.9456.CrossRefPubMedPubMedCentral

83.

Heizer JW, Borgelt LM, Bashqoy F, Wang GS, Reiter PD. Marijuana misadventures in children: Exploration of a dose-response relationship and summary of clinical effects and outcomes. Pediatr Emerg Care. 2018;34(7):457–62. https://doi.org/10.1097/PEC.0000000000000770.CrossRefPubMed

84.

MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12–9. https://doi.org/10.1016/j.ejim.2018.01.004.CrossRefPubMed

85.

California Department of Public Health. Manufactured Cannabis Safety Branch. Accessed 17 May 2019 at https://www.cdph.ca.gov/Programs/CEH/DFDCS/MCSB/Pages/PackagingandLabelingFAQs.aspx

86.

Colorado Marijuana. New Colorado rules make marijuana packaging safer for adults, less appealing to children. Accessed 17 May 2019 at https://www.colorado.gov/pacific/marijuana/news/new-colorado-rules-make-marijuana-packaging-safer-adults-less-appealing-children

87.

Thomas AA, Mazor S. Unintentional marijuana exposure presenting as altered mental status in the pediatric emergency department: A case series. J Emerg Med. 2017;53(6):e119–23. https://doi.org/10.1016/j.jemermed.2017.08.007.CrossRefPubMed

88.

Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004;53:1566–70.CrossRefPubMedPubMedCentral

89.

Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid Hyperemesis Syndrome: Diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13(1):71–87. https://doi.org/10.1007/s13181-016-0595-z.CrossRefPubMed

90.

Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–92.CrossRefPubMed

91.

Suzuki H. The application of the Rome IV criteria to functional esophagogastroduodenal disorders in Asia. J Neurogastroenterol Motil. 2017;23(3):325–33.CrossRefPubMedPubMedCentral

92.

Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid Hyperemesis Syndrome. Curr Drug Abuse Rev. 2011;4(4):241–9.CrossRefPubMedPubMedCentral

93.

Bollom A, Austrie J, Hirsch W, Nee J, Friedlander D, Iturrino J, Ballou S, Lembo A. Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder: US Trends From 2006 to 2013. J Clin Gastroenterol. 2018;52(9):778–83. https://doi.org/10.1097/MCG.0000000000000944.CrossRefPubMedPubMedCentral

94.

Richards JR, Gordon BK, Danielson AR, Moulin AK. Pharmacologic treatment of cannabinoid hyperemesis syndrome: A systematic review. Pharmacotherapy. 2017;37(6):725–34. https://doi.org/10.1002/phar.1931.CrossRefPubMed

95.

Khattar N, Routsolias JC. Emergency department treatment of Cannabinoid Hyperemesis Syndrome: A review. Am J Ther. 2018;25(3):e357–61. https://doi.org/10.1097/MJT.0000000000000655.CrossRefPubMed

96.

Richards JR. Cannabinoid Hyperemesis Syndrome: Pathophysiology and treatment in the emergency department. J Emerg Med. 2018;54(3):354–63. https://doi.org/10.1016/j.jemermed.2017.12.010.CrossRefPubMed

97.

Hammerman S, Shelton S, Mills E, et al. Antiemetics effectiveness for Cannabinoid Hyperemesis Syndrome (CHS) emergency department (ED) encounters. North American Congress of Clinical Toxicology (NACCT) Abstracts 2019. Clin Toxicol. 2019:8. https://doi.org/10.1080/15563650.2019.1636569.

98.

Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol (Phila). 2019;57(9):773–7. https://doi.org/10.1080/15563650.2018.1564324.CrossRef

99.

Gan TJ, Diemunsch P, Habib AS, et al. Consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2014;118(1):85–113. https://doi.org/10.1213/ANE.0000000000000002.CrossRefPubMed

100.

Nourbakhsh M, Miller A, Gofton J, Jones G, Adeagbo B. Cannabinoid Hyperemesis Syndrome: Reports of fatal cases. J Forensic Sci. 2019;64(1):270–4. https://doi.org/10.1111/1556-4029.13819.CrossRefPubMed

101.

Schreck B, Wagneur N, Caillet P, et al. Cannabinoid hyperemesis syndrome: Review of the literature and of cases reported to the French addictovigilance network. Drug Alcohol Depend. 2018;182:27–32. https://doi.org/10.1016/j.drugalcdep.2017.09.038.CrossRefPubMed

102.

Hernandez JM, Paty J, Price IM. Cannabinoid hyperemesis syndrome presentation to the emergency department: A two-year multicentre retrospective chart review in a major urban area. CJEM. 2018;20(4):550–5. https://doi.org/10.1017/cem.2017.381.CrossRefPubMed

103.

Fraser JD. Withdrawal symptoms in cannabis indica addicts. Lancet. 1949;2(6582):747. https://doi.org/10.1016/s0140-6736(49)92263-1.CrossRefPubMed

104.

Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94:1311–22. https://doi.org/10.1046/j.1360-0443.1999.94913114.x.CrossRefPubMed

105.

Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry. 2008;69(9):1354–63. https://doi.org/10.4088/jcp.v69n0902.CrossRefPubMedPubMedCentral

106.

Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug Alcohol Depend. 2019;195:170–7. https://doi.org/10.1016/j.drugalcdep.2018.09.005.CrossRefPubMed

107.

Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids: A systematic review and meta-analysis. JAMA Netw Open. 2020;3:e202370. https://doi.org/10.1001/jamanetworkopen.2020.2370.CrossRefPubMedPubMedCentral

108.

Schlienz NJ, Budney AJ, Lee DC, Vandrey R. Cannabis withdrawal: A review of neurobiological mechanisms and sex differences. Curr Addict Rep. 2017;4(2):75–81. https://doi.org/10.1007/s40429-017-0143-1.CrossRefPubMedPubMedCentral

109.

Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abus Rehabil. 2017;8:9–37. https://doi.org/10.2147/SAR.S109576.CrossRef

110.

Gorelick DA. Pharmacological treatment of cannabis-related disorders: A narrative review. Curr Pharm Des. 2016;22:6409–19. https://doi.org/10.2174/1381612822666160822150822.CrossRefPubMed

111.

Brezing CA, Levin FR. The current state of pharmacological treatments for cannabis use disorder and withdrawal. Neuropsychopharmacology. 2018;43:173–94. https://doi.org/10.1038/npp.2017.212.CrossRefPubMed

112.

Nielsen S, Gowing L, Sabioni P, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2019;1:CD008940. https://doi.org/10.1002/14651858.CD008940.pub3.CrossRefPubMed

113.

Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86:22–9. https://doi.org/10.1016/j.drugalcdep.2006.04.014.CrossRefPubMed

114.

Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal. JAMA Psychiatry. 2014;71:281. https://doi.org/10.1001/jamapsychiatry.2013.3947.CrossRefPubMed

115.

Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013;38:1557–65. https://doi.org/10.1038/npp.2013.54.CrossRefPubMedPubMedCentral

116.

Schlienz NJ, Lee DC, Stitzer ML, Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018;187:254–60. https://doi.org/10.1016/j.drugalcdep.2018.02.022.CrossRefPubMedPubMedCentral

117.

Werneck MA, Kortas GT, de Andrade AG, Castaldelli-Maia JM. A systematic review of the efficacy of cannabinoid agonist replacement therapy for cannabis withdrawal symptoms. CNS Drugs. 2018;32(12):1113–29. https://doi.org/10.1007/s40263-018-0577-6.CrossRefPubMed

118.

Zhand N, Milin R. What do we know about the pharmacotheraputic management of insomnia in cannabis withdrawal: A systematic review. Am J Addict. 2018;27(6):453–64. https://doi.org/10.1111/ajad.12783.CrossRefPubMed

119.

CDC. Severe pulmonary disease associated with using e-cigarette products. HAN alert No. 421. Atlanta: US Department of Health and Human Services, CDC, Health Alert Network; 2019. https://emergency.cdc.gov/han/han00421.asp

120.

Siegel DA, Jatlaoui TC, Koumans EH, et al. Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury — United States, October 2019. MMWR Morb Mortal Wkly Rep. 2019;68(41):919–27. https://doi.org/10.15585/mmwr.mm6841e3.CrossRefPubMedPubMedCentral

121.

Ellington S, Salvatore PP, Ko J, et al. Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, August 2019–January 2020. MMWR Morb Mortal Wkly Rep. 2020;69(2):44–9. https://doi.org/10.15585/mmwr.mm6902e2.CrossRefPubMedPubMedCentral

122.

Blount BC, Karwowski MP, Shields PG, et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med. 2020;382(8):697–705. https://doi.org/10.1056/NEJMoa1916433.CrossRefPubMed

123.

Centers for Disease Control and Prevention. Outbreak of lung injury associated with e-cigarette use, or vaping. Accessed 30 March 2020 at https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html

124.

Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations and deaths associated with EVALI. N Engl J Med. 2020;382:1589–98. https://doi.org/10.1056/NEJMoa1915314.CrossRefPubMedPubMedCentral

125.

Schier JG, Meiman JG, Layden J, et al. Severe Pulmonary Disease Associated with Electronic-Cigarette–Product Use — Interim Guidance. MMWR Morb Mortal Wkly Rep. 2019;68(36):787–90. https://doi.org/10.15585/mmwr.mm6836e2.CrossRefPubMedPubMedCentral

126.

Jatlaoui TC, Wiltz JL, Kabbani S, et al. Update: Interim Guidance for Health Care Providers for Managing Patients with Suspected E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, November 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1081–6. https://doi.org/10.15585/mmwr.mm6846e2 Published online 2019 Nov 22.CrossRefPubMedPubMedCentral

127.

Chatham-Stephens K, Roguski K, Jang Y, et al. Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, November 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1076–80. https://doi.org/10.15585/mmwr.mm6846e1.CrossRefPubMedPubMedCentral

128.

Seely KA, Prather PL, James LP, Moran JH. Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv. 2011;11:36–51.CrossRefPubMedPubMedCentral

129.

Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuro-Psychopharmacol Biol Psychiatry. 2012;39(2):234–43. https://doi.org/10.1016/j.pnpbp.2012.04.017.CrossRef

130.

Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41. https://doi.org/10.1016/j.drugalcdep.2014.08.005.CrossRefPubMed

131.

Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 2011;3(7-8):466–78. https://doi.org/10.1002/dta.268.CrossRefPubMed

132.

Tournebize J, Gibaja V, Kahn JP. Acute effects of synthetic cannabinoids: Update 2015. Subst Abus. 2017;38(3):344–66. https://doi.org/10.1080/08897077.2016.1219438.CrossRefPubMed

133.

Courts J, Maskill V, Gray A, Glue P. Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Australas Psychiatry. 2016;24(6):598–601. https://doi.org/10.1177/1039856216663733.CrossRefPubMed

134.

Monte AA, Calello DP, Gerona RR, et al. Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC Database study. J Med Toxicol. 2017;13(2):146–52.CrossRefPubMedPubMedCentral

135.

Rowley E, Benson D, Tiffee A, et al. Clinical and financial implications of emergency department visits for synthetic marijuana. Am J Emerg Med. 2017;35(10):1506–9. https://doi.org/10.1016/j.ajem.2017.04.044.CrossRefPubMed

136.

Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435–8. https://doi.org/10.1016/j.annemergmed.2012.03.007.CrossRefPubMed

137.

Centers for Disease Control and Prevention (CDC). Notes from the field: severe illness associated with reported use of synthetic marijuana - Colorado, August-September 2013. MMWR Morb Mortal Wkly Rep. 2013;62(49):1016–7.

138.

Johnson LA, Johnson RL, Portier RB. Current "legal highs". J Emerg Med. 2013;44(6):1108–15. https://doi.org/10.1016/j.jemermed.2012.09.147.CrossRefPubMed

139.

Gottlieb S, Marks P. Statement from FDA warning about significant health risks of contaminated illegal synthetic cannabinoid products that are being encountered by FDA. Accessed 19 Dec 2018 at https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm614027.htm

140.

Adams AJ, Banister SD, Irizarry L, Trecki J, Schwartz M, Gerona R. "Zombie" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N Engl J Med. 2017;376(3):235–42. https://doi.org/10.1056/NEJMoa1610300.CrossRefPubMed

141.

Kelkar AH, Smith NA, Martial A, Moole H, Tarantino MD, Roberts JC. An outbreak of synthetic cannabinoid-associated coagulopathy in Illinois. N Engl J Med. 2018;379(13):1216–23. https://doi.org/10.1056/NEJMoa1807652.CrossRefPubMed

142.

Winstock AR, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol. 2015;29:698–703. https://doi.org/10.1177/0269881115574493.CrossRefPubMed

143.

Zaurova M, Hoffman RS, Vlahov D, Manini AF. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol. 2016;12(4):335–40. https://doi.org/10.1007/s13181-016-0558-4.CrossRefPubMedPubMedCentral

144.

Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54:1–13. https://doi.org/10.3109/15563650.2015.1110590.CrossRef

145.

Law R, Schier J, Martin C, Chang A, Wolkin A. Notes from the field: Increase in reported adverse health effects related to synthetic cannabinoid use — United States, January–May 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):618–9.PubMedPubMedCentral

146.

Wohlfarth A, Scheidweiler KB, Chen X, Liu H, Huestis MA. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC–MS/MS and library search. Anal Chem. 2013;85(7):3730–8. https://doi.org/10.1021/ac3037365.CrossRefPubMed

147.

Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol. 2013;37(5):284–90. https://doi.org/10.1093/jat/bkt024.CrossRefPubMed

148.

Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol. 2015;33:175–94. https://doi.org/10.1007/s11419-015-0270-0.CrossRefPubMedPubMedCentral

149.

Adamowicz P, Tokarczyk B. Simple and rapid screening procedure for 143 new psychoactive substances by liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2016;8(7):652–67. https://doi.org/10.1002/dta.1815.CrossRefPubMed

150.

Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep. 2015;5:8126. https://doi.org/10.1038/srep08126.CrossRefPubMedPubMedCentral

151.

WikiLeaf. Which states have the highest taxes on marijuana? Priceoneconomics, 3/6/19. Accessed 24 June 2020 at https://priceonomics.com/which-states-have-highest-taxes-on-marijuana/

152.

Takakuwa KM, Mistretta A, Pazdernik VK, Sulak D. Education, knowledge, and practice characteristics of cannabis physicians: A survey of the Society of Cannabis Clinicians. Cannabis Cannabinoid Res. Published online 23 Aug 2019, https://doi.org/10.1089/can.2019.0025.

153.

Takakuwa KM, Shofer FS, Schears RM. The practical knowledge, experience and beliefs of US emergency medicine physicians regarding medical cannabis: A national survey. Am J Emerg Med. 2020;S0735-6757(20):30071. https://doi.org/10.1016/j.ajem.2020.01.059.CrossRef

154.

Takakuwa KM, Shofer FS, Schears RM. A national survey of US emergency medicine physicians on their knowledge regarding state and federal cannabis laws. Cannabis Cannabinoid Res. Published online 11 Feb 2020, https://doi.org/10.1089/can.2019.0073.

Title: The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review
Authors: Kevin M. Takakuwa
Raquel M. Schears
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Intoxication
Cannabinoid
Care
Published in: International Journal of Emergency Medicine / Issue 1/2021
Print ISSN: 1865-1372
Electronic ISSN: 1865-1380
DOI: https://doi.org/10.1186/s12245-021-00330-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Protecting providers and patients: results of an Internet survey of health care workers’ risk perceptions and ethical concerns during the COVID-19 pandemic

Personal protective equipment and doffing procedures in out-of-hospital practice: assessment with a contamination simulation

Subarachnoid hemorrhage in the emergency department

Spontaneous globe subluxation: a case report and review of the literature

Incidence and prevalence of violence toward health care workers in emergency departments: a multicenter cross-sectional survey

Lack of racial and ethnic-based differences in acute care delivery in intracerebral hemorrhage